IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-49092-5.html
   My bibliography  Save this article

Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial

Author

Listed:
  • Mary M. McDermott

    (Department of Medicine
    Department of Preventive Medicine)

  • Christopher R. Martens

    (Department of Kinesiology & Applied Physiology)

  • Kathryn J. Domanchuk

    (Department of Medicine)

  • Dongxue Zhang

    (Department of Medicine)

  • Clara B. Peek

    (Department of Medicine
    Department of Biochemistry and Molecular Genetics)

  • Michael H. Criqui

    (Division of Preventive Medicine)

  • Luigi Ferrucci

    (Division of Intramural Research)

  • Philip Greenland

    (Department of Medicine
    Department of Preventive Medicine)

  • Jack M. Guralnik

    (Department of Epidemiology and Public Health)

  • Karen J. Ho

    (Department of Surgery)

  • Melina R. Kibbe

    (Department of Surgery)

  • Kate Kosmac

    (Department of Physical Therapy)

  • Donald Lloyd-Jones

    (Department of Medicine
    Department of Preventive Medicine)

  • Charlotte A. Peterson

    (Center for Muscle Biology)

  • Robert Sufit

    (Department of Neurology)

  • Lu Tian

    (Department of Health Research and Policy)

  • Stephanie Wohlgemuth

    (Department of Physiology and Aging)

  • Lihui Zhao

    (Department of Preventive Medicine)

  • Pei Zhu

    (Department of Medicine
    Department of Biochemistry and Molecular Genetics)

  • Christiaan Leeuwenburgh

    (Department of Physiology and Aging)

Abstract

People with lower extremity peripheral artery disease (PAD) have increased oxidative stress, impaired mitochondrial activity, and poor walking performance. NAD+ reduces oxidative stress and is an essential cofactor for mitochondrial respiration. Oral nicotinamide riboside (NR) increases bioavailability of NAD+ in humans. Among 90 people with PAD, this randomized double-blind clinical trial assessed whether 6-months of NR, with and without resveratrol, improves 6-min walk distance, compared to placebo, at 6-month follow-up. At 6-month follow-up, compared to placebo, NR significantly improved 6-min walk (+7.0 vs. −10.6 meters, between group difference: +17.6 (90% CI: + 1.8,+∞). Among participants who took at least 75% of study pills, compared to placebo, NR improved 6-min walk by 31.0 meters and NR + resveratrol improved 6-min walk by 26.9 meters. In this work, NR meaningfully improved 6-min walk, and resveratrol did not add benefit to NR alone in PAD. A larger clinical trial to confirm these findings is needed. Clinical Trials.gov registration: NCT03743636.

Suggested Citation

  • Mary M. McDermott & Christopher R. Martens & Kathryn J. Domanchuk & Dongxue Zhang & Clara B. Peek & Michael H. Criqui & Luigi Ferrucci & Philip Greenland & Jack M. Guralnik & Karen J. Ho & Melina R. K, 2024. "Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial," Nature Communications, Nature, vol. 15(1), pages 1-11, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-49092-5
    DOI: 10.1038/s41467-024-49092-5
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-49092-5
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-024-49092-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Konrad T. Howitz & Kevin J. Bitterman & Haim Y. Cohen & Dudley W. Lamming & Siva Lavu & Jason G. Wood & Robert E. Zipkin & Phuong Chung & Anne Kisielewski & Li-Li Zhang & Brandy Scherer & David A. Sin, 2003. "Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan," Nature, Nature, vol. 425(6954), pages 191-196, September.
    2. Christopher R. Martens & Blair A. Denman & Melissa R. Mazzo & Michael L. Armstrong & Nichole Reisdorph & Matthew B. McQueen & Michel Chonchol & Douglas R. Seals, 2018. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults," Nature Communications, Nature, vol. 9(1), pages 1-11, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Eliot L. Sherman, 2020. "Discretionary Remote Working Helps Mothers Without Harming Non-mothers: Evidence from a Field Experiment," Management Science, INFORMS, vol. 66(3), pages 1351-1374, March.
    2. Salvador Manzo-Avalos & Alfredo Saavedra-Molina, 2010. "Cellular and Mitochondrial Effects of Alcohol Consumption," IJERPH, MDPI, vol. 7(12), pages 1-24, December.
    3. Haakon Berven & Simon Kverneng & Erika Sheard & Mona Søgnen & Solveig Amdahl Af Geijerstam & Kristoffer Haugarvoll & Geir-Olve Skeie & Christian Dölle & Charalampos Tzoulis, 2023. "NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    4. Patricia R. Pitrez & Luis M. Monteiro & Oliver Borgogno & Xavier Nissan & Jerome Mertens & Lino Ferreira, 2024. "Cellular reprogramming as a tool to model human aging in a dish," Nature Communications, Nature, vol. 15(1), pages 1-11, December.
    5. Robin Haunschild & Werner Marx, 2022. "On Health Effects of Resveratrol in Wine," IJERPH, MDPI, vol. 19(5), pages 1-13, March.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-49092-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.